



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 06/26/2019 07:09
Last Report Issued 03/25/2019 10:33

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 8098B-POS
Patient ID 8098B-POS
Chain 19000548
Age Not Given DOB Not Given
Gender Not Given
Workorder 19000548
Received 03/19/2019 13:57

Sample ID 19000548-001
Matrix Blood
Patient Name 8098B-POS
Patient ID 8098B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

8098B Drug Screen (GC/MS), Blood

Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)

Other Findings None Found

Comment: The following is a general list of compound classes included in the Gas Chromatographic screen. The detection of any particular compound is concentration-dependent. Please note that not all known compounds included in each specified class or heading are included. Some specific compounds outside these classes are also included. For a detailed list of all compounds and reporting limits included in this screen, please contact NMS Labs.

- Amphetamines, Analgesics (opioid and non-opioid), Anorectics, Antiarrhythmics, Anticholinergic Agents, Anticonvulsant Agents, Antidepressants, Antiemetic Agents, Antihistamines, Antiparkinsonian Agents, Antipsychotic Agents, Antitussive Agents, Antiviral Agents, Calcium Channel Blocking Agents, Cardiovascular Agents (non-digitalis), Local Anesthetics Agents, Muscle Relaxants and Stimulants (Amphetamine-like and others).

Analysis by Gas Chromatography/Mass Spectrometry (GC/MS)

Results for sample 19000548-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 19000548-001
Matrix Blood
Patient Name 8098B-POS
Patient ID 8098B-POS

Collect Dt/Tm Not Given
Source Not Given

Table header with columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

Other Findings None Found

52235B Bath Salts Confirmation, Blood

Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)

alpha-PVP 20 ng/mL 2.0

Synonym(s): (RS)-1-phenyl-2-(1-pyrrolidinyl)-1-pentanone; alpha-Pyrrolidinovalerophenone

Alpha-Pyrrolidinovalerophenone (alpha-PVP) is a psychoactive stimulant that is structurally related to pyrovalerone and MDPV. The compound has been sold on the internet as a designer drug for the intention of recreational drug use in the form of tablets or powders to be taken orally or insufflated, respectively. It is abused for its perceived 'ecstasy like' effects of euphoria, excitement and alertness. It is claimed that alpha-PVP improves productivity, wakefulness, motivation, locomotion and endurance. In general, psychoactive stimulants have temporary effects on the psychoneurotic system. In addition, they seem to have a much higher tendency to cause side effects such as paranoia, hallucinations, and schizophrenic or psychosis like symptoms. Serum concentrations in 2 fatalities were 410 and 1500 ng/mL. A serum concentration in a case where the individual presented to the ED with visual hallucinations, psychotic symptoms, tachycardia, and rhabdomyolysis was 235 ng/mL; other impairing drugs were often found in conjunction with Alpha PVP. The blood to plasma ratio for alpha-PVP is not known.

Methoxetamine 20 ng/mL 2.0

Synonym(s): 2-MeO-Oxo-PC; MXE

Methoxetamine is a psychoactive compound that is structurally related to ketamine and reported to have similar effects. Ketamine is a DEA Schedule III rapidly acting general anesthetic that is chemically related to phencyclidine (PCP). The effects of ketamine include profound analgesia, normal or enhanced skeletal muscle tone and cardiovascular and respiratory stimulation. Reactions manifested by hallucinations, delirium, irrational behavior and/or dream-like states may be seen with use of ketamine and, presumably, methoxetamine. The use of methoxetamine has been

Results for sample 19000548-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 19000548-001
Matrix Blood
Patient Name 8098B-POS
Patient ID 8098B-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains detailed text for Butylone and Dibutylone.

Results for sample 19000548-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 19000548-001
Matrix Blood
Patient Name 8098B-POS
Patient ID 8098B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
<p>Dibutylone is a substituted cathinone that is sold recreationally as a novel psychoactive substance. Butylone may be present due to being a potential metabolite of dibutylone; butylone itself is also considered a novel psychoactive substance. It has been identified in some 'bath salt' or 'research chemical' type products for euphoric and empathogenic effects. The drug is usually taken orally, but can also be insufflated or vaporized.</p>				
<p>N-Ethyl Pentylone</p> <p>N-Ethyl Pentylone is a substituted cathinone structurally similar to pentylone. It is sold as a novel psychoactive substance. Due to its structural similarities to pentylone, N-Ethyl Pentylone is expected to have stimulant type effects. N-Ethyl Pentylone was reported as the sole intoxicant in a fatality where an individual was agitated and displayed erratic behavior followed by cardiac arrest; other symptoms included rhabdomyolysis, hypoglycemia, hepatic and renal injury, respiratory failure, and disseminated intravascular coagulation.</p>	50	ng/mL	10	